Eversana, Accord BioPharma: launch of Camcevi prostate cancer treatment
Accord BioPharma is joining forces with Eversana to launch its Camcevi (leuprolide) 42mg injection emulsion for advanced prostate cancer treatment. Accord BioPharma is heading US distribution for the drug, which received approval from the US Food and Drug Administration from Foresee Pharmaceuticals.
“Accord Healthcare has been offering quality pharmaceutical products in the U.S. and globally since the early 2000s. Through this strategic partnership with EVERSANA for the launch of CAMCEVI, we are excited to sharpen Accord BioPharma's focus on specialty pharmaceuticals. This will help us enable better access to therapy for advanced prostate cancer patients across the US,” said Binish Chudgar, managing director of Accord Healthcare and Accord BioPharma.
